The breast surgeon's role in BRCA1 and BRCA2 testing

American Journal of Surgery

Volumn 180, Issue 4, 2000, Pages 294-298

  Matloff, Ellen T ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SURGERY; CHEMOPROPHYLAXIS; CONFERENCE PAPER; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; HUMAN; MASTECTOMY; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURGEON; TREATMENT PLANNING;

BRCA2 PROTEIN; BREAST; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENETIC MARKERS; GENETIC SCREENING; HUMANS; NEOPLASM PROTEINS; PEDIGREE; RISK ASSESSMENT; TRANSCRIPTION FACTORS;

EID: 0033653485     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(00)00460-8     Document Type: Conference Paper

References (36)

1. The genetic attributable risk of breast and ovarian cancer
2. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
3. Identification of the breast cancer susceptibility gene BRCA2
4. Risks of cancer in BRCA1-mutation carriers
5. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashenazi jews
6. Complexities in cancer genetic counseling: Breast and ovarian cancer
7. Breast and ovarian cancer incidence in BRCA1-mutation carriers
8. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
9. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families
10. Familial breast cancer: Recent advances
11. Cancer risks in BRCA2 mutation carriers
12. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer
13. BRCA1 mutations in a population-based sample of young women with breast cancer
14. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer
15. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
16. Indications for prophylactic mastectomy
17. Bilateral primary breast cancers
18. Long-term follow-up of breast cancer patients: The 30-year report
19. Evaluation of patients after primary therapy
20. Familial breast cancer: Risk to the contralateral breast
21. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implications for breast-conserving management in patients with BRCA1/BRCA2 mutations
22. The woman at increased risk for breast cancer: Evaluation and management strategies
23. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
24. Bilateral prophylactic mastectomy (PM) in BRCA1/2 mutation carriers
25. BRCA1 testing in families with hereditary breast-ovarian cancer: A prospective study of patient decision making and outcomes
26. Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
27. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women
28. Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2
29. Prophylactic oophorectomy in inherited breast/ovarian cancer families
30. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry
31. Hormone replacement therapy in women with breast cancer: Do the risks outweigh the benefits?
32. Inherited breast and ovarian cancer: What are the risks? what are the choices?
33. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers
34. Oral contraceptives and the risk of hereditary ovarian cancer
35. Breast cancer genetics: Toward molecular characterization of individuals at increased risk for breast cancer: Part II
36. The impact of genetic screening on surgical decision making in breast cancer